Quality Systems – Page 256

Ivrt Failure during scale-up: root cause mapping across materials and process

Root Cause Mapping for IVRT Failures during Scale-Up in Pharmaceutical Manufacturing In the highly regulated world of pharmaceutical manufacturing, any deviations or out-of-specification (OOS) results can lead to significant disruptions,…

Osmolality Oos at stability pull: CAPA and effectiveness check plan

Osmolality is a critical parameter in ensuring the quality of pharmaceutical formulations, particularly in ophthalmic dosage forms. When an out-of-specification (OOS) result occurs during a stability pull, it can lead…

Dose Delivery Variability during lamination: inspection-ready documentation pack

Addressing Variability in Dose Delivery during Lamination: A Comprehensive Investigation In pharmaceutical manufacturing, particularly in the development of transdermal drug delivery systems, maintaining consistent dose delivery is crucial. When variability…

Texture Variability at accelerated stability: packaging compatibility and stability justification

Understanding Texture Variability During Accelerated Stability Testing in Pharmaceutical Manufacturing Texture variability observed during accelerated stability testing can raise significant concerns regarding product quality and consistency, particularly for topical and…

Ivpt Failure in transdermal patch manufacturing: packaging integrity and shelf-life justification

Investigation of IVPT Failures during Transdermal Patch Manufacturing: Packaging Integrity and Shelf-Life Considerations In the increasingly complex landscape of pharmaceutical manufacturing, ensuring the integrity and efficacy of transdermal patches poses…

Texture Variability during shared equipment campaign: GMP investigation and CAPA strategy

Investigating Texture Variability in Shared Equipment Campaigns: Identifying Causes and Implementing CAPA In the realm of pharmaceutical manufacturing, maintaining the quality of topical and dermatological dosage forms is paramount. One…

Drug Crystallization after backing material change: GMP investigation plan and CAPA

Understanding Drug Crystallization Following Changes to Backing Material: An Effective Investigation Framework In the pharmaceutical sector, changes in materials can yield unexpected issues, such as drug crystallization, particularly when dealing…

E&L Failure during method transfer: sampling, filtration, and EM controls

Addressing E&L Failures during Method Transfers: A Structured Investigation Approach During method transfers in pharmaceutical manufacturing, specifically in the production of ophthalmic dosage forms, extraction and leachable (E&L) failures can…

Ph Drift during homogenization: mixing and sampling controls for QA review

Understanding pH Drift During Homogenization and Ensuring Robust Mixing Controls for QA Review In pharmaceutical manufacturing, maintaining consistent product quality is critical for regulatory compliance and patient safety. One frequent…

Backing Delamination at accelerated stability: process parameter review and validation impact

Investigating Backing Delamination at Accelerated Stability: A Systematic Approach Backing delamination in transdermal drug delivery systems can significantly impact product integrity, therapeutic efficacy, and regulatory compliance. When delamination occurs during…

Viscosity Drift during bulk hold: GMP investigation and CAPA strategy

Addressing Viscosity Drift during Bulk Hold: A Comprehensive Investigation and CAPA Framework In pharmaceutical manufacturing, viscosity is a critical parameter that directly impacts the quality and performance of topical and…

Edge Lifting after adhesive change: root cause mapping across materials and process

Root Cause Analysis of Edge Lifting Following Adhesive Change in Transdermal Systems The phenomenon of edge lifting after adhesive change is a significant quality issue within transdermal drug delivery systems.…